マーケットレポート詳細

次世代がん診断：技術および世界市場2027年予測

Next-Generation Cancer Diagnostics: Technologies and Global Markets

出版元：BCC Research 　 出版元について
発行年：2023年5月
定価 ：Single User License(1名様ライセンス)US$5,500 (米国ドル) /2 to 5 Users License(5名様)$6,600 /Site License $7,920 / Enterprise License $9,504
ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
ご請求は円換算（お見積り日TTSレート）となります。
納品形態：PDF by Email
当調査レポートは英文166ページになります。
商品コード：BCC457

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。

【レポート紹介】

次世代がん診断の世界市場規模は2022年で87億ドル、2027年に150億ドル、市場の平均年成長率は11.5%になると予測されています。

当レポートでは、次世代がん診断の市場/技術的背景、各種セグメント別市場分析(部位別、国地域別)、市場と技術の背景、がん診断市場、主要企業プロフィールなどを盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】

◆イントロダクション

・調査目的
・調査対象
・調査手法

◆サマリーと調査ハイライト

◆市場と技術の背景

・個別化医療における次世代シーケンシング（NGS）
・臨床腫瘍学におけるNGS
・大規模な取組/コンソーシアム
・リキッドバイオプシー技術
・市場促進力としてのリキッドバイオプシー
・産業
・診断概要
・配列/マイクロ流体力学技術
・従来技術の多重化
・PCR（ポリメラーゼ連鎖反応）技術

◆がん診断市場

成長推進力
部位別次世代がん診断市場
目的別次世代がん診断市場
・早期発見/スクリーニング
・診断
・モニタリング

テストプラットフォーム別次世代がん診断市場
・PCR
・NGS
・アレイ/マイクロ流体
・細胞/EV
・マルチプレックス

部位別テストプラットフォーム市場
診断セグメント別市場

◆次世代がん診断市場：部位別

・膀胱がん
・脳腫瘍
・乳がん
・婦人科がん
・結腸直腸がん
・原発不明がん
・胃がん
・腎臓がん
・血液検査：白血病/骨髄腫
・肝臓がん
・肺がん
・血液検査：リンパ腫
・メラノーマ（悪性黒色腫）
・汎がん
・前立腺がん
・甲状腺がん
※市場予測データ掲載-2027年

◆最先端技術

・集団シーケンシングプログラム
・CRISPR

◆次世代がん診断市場：地域別市場予測

・北米
・欧州
・アジア太平洋
・その他地域
※市場予測データ掲載-2027年

◆特許状況

◆次世代がん診断市場の主要企業プロフィール

・ABBOTT LABORATORIES
・ABBVIE INC.
・ADVANCED CELL DIAGNOSTICS INC.
・AGILENT TECHNOLOGIES
・ARTIVION INC.
・BECTON, DICKINSON AND CO.
・BENITEC BIOPHARMA LTD.
・CALADRIUS BIOSCIENCES
・CELGENE CORP.
・COMMENCE BIO
・DEPUY SYNTHES (J&J)
・DRAGERWERK AG & CO. KGAA
・EPIC SCIENCES INC.
・GENEXINE
・GERON
・ILLUMINA INC.
・IMMUNOCELLULAR THERAPEUTICS
・INEX INNOVATIONS EXCHANGE PTE. LTD.
・INIVATA LTD.
・INTERPACE DIAGNOSTICS LLC
・INVIVOSCRIBE INC.
・MEDTRONIC PLC
・MERCK KGAA
・NOVARTIS AG
・ONCOCYTE CORP.
・ONCOMED PHARMACEUTICALS INC.
・PLURISTEM THERAPEUTICS INC.
・SILICON BIOSYSTEMS S.P.A
・SPHERE FLUIDICS LTD.
・THERMO FISHER SCIENTIFIC
・VITATEX INC.

（全166頁）
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】

Table of Contents (英文詳細目次）

Chapter 1 Introduction

1.1 Study Goals and Objectives
1.2 Reasons for Doing This Study
1.3 Scope of Report
1.4 What’s New in This Update?
1.5 Information Sources and Methodology

  • 1.5.1 Secondary Research
  • 1.5.2 Primary Research

1.6 Research Methodology
1.7 Geographic Breakdown
1.8 Analyst’s Credentials
1.9 BCC Custom Research
1.10 Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

3.1 Overview
3.2 Next Generation Sequencing in Personalized Medicine

  • 3.2.1 Cost-Effective
  • 3.2.2 Samples Required

3.3 NGS in Clinical Oncology

  • 3.3.1 Accurate Detection of Genetic Mutations
  • 3.3.2 Precision Diagnostics
  • 3.3.3 Tumor Genomic Profiling

3.4 Large-Scale Initiatives and Consortia
3.5 Liquid Biopsy Technologies
3.6 Liquid Biopsy as a Market-Driving Force

  • 3.6.1 Key Trends

3.7 Industry
3.8 Diagnostics Overview
3.9 Arrays and Microfluidics (LOAC) Technologies

  • 3.9.1 DNA Microarrays
  • 3.9.2 Protein Microarrays
  • 3.9.3 Microfluidics

3.10 Multiplex Conventional Technologies
3.11 Polymerase Chain Reaction (PCR) Technology

Chapter 4 Cancer Diagnostics Market

4.1 Forces Driving Growth
4.2 Cancer Markets
4.3 Market for Next-Generation Cancer Diagnostics by Cancer Site

  • 4.3.1 Bladder Cancer
  • 4.3.2 Brain Cancer
  • 4.3.3 Breast Cancer

4.4 Market for Next-Generation Cancer Diagnostics by Purpose of Analysis

  • 4.4.1 Screening/Early Detection Market
  • 4.4.2 Diagnostics Market
  • 4.4.3 Therapy Guidance Market
  • 4.4.4 Monitoring Market

4.5 Market for Next-Generation Cancer Diagnostics by Test Platform

  • 4.5.1 PCR Test Platform
  • 4.5.2 NGS Test Platform
  • 4.5.3 Array/Microfluidics Test Platform
  • 4.5.4 Cells and/or EV Capture Test Platform
  • 4.5.5 Multiplex Conventional Test Platform

4.6 Market for Test Platforms by Cancer Site

  • 4.6.1 PCR Test Platform
  • 4.6.2 NGS Test Platform

4.7 Market by Diagnostic Segment

  • 4.7.1 Screening/Early Detection Market
  • 4.7.2 Diagnostics Market
  • 4.7.3 Monitoring Market
  • 4.7.4 Therapy Guidance Market
  • 4.7.5 Breast Cancer Diagnostics
  • 4.7.6 Digestive Cancer Diagnostics
  • 4.7.7 Respiratory and Skin Cancer Diagnostics

Chapter 5 Market Breakdown Application by Cancer Site

5.1 Overview
5.2 Bladder Cancer
5.3 Brain Cancer

  • 5.3.1 Types of Brain Cancer

5.4 Breast Cancer

  • 5.4.1 Risk
  • 5.4.2 Breast Cancer Screening
  • 5.4.3 Prognosis and Pharmacogenetics Tests
  • 5.4.4 Breast Cancer MDx Platforms
  • 5.4.5 Status of Next-Generation Breast Cancer Tests
  • 5.4.6 Treatment

5.5 Gynecologic Cancers

  • 5.5.1 Cervical Cancer
  • 5.5.2 Ovarian Cancer

5.6 Colorectal Cancer

  • 5.6.1 Conventional Colorectal Cancer Screening Tests
  • 5.6.2 Next-Generation Colorectal Cancer Diagnostic Tests

5.7 Cancer Unknown Primary
5.8 Gastric Cancer
5.9 Kidney Cancer
5.10 Hematologic Tests: Leukemia and Myeloma
5.11 Liver Cancer
5.12 Lung Cancer
5.13 Hematologic Tests: Lymphomas
5.14 Melanoma
5.15 Pan-Cancer
5.16 Prostate Cancer
5.17 Thyroid Cancer

Chapter 6 Emerging Technologies

6.1 Overview
6.2 Population Sequencing Programs
6.3 Introduction
6.4 CRISPR

Chapter 7 Evaluation of the Market Based on Geographic Region

7.1 Overview of the Geographical Distribution of the Market
7.2 Overview
7.3 North America
7.4 Europe
7.5 Asia-Pacific
7.6 Rest of the World

Chapter 8 Patents

Chapter 9 Company Profiles

ABBOTT LABORATORIES
ABBVIE INC.
ADVANCED CELL DIAGNOSTICS INC.
AGILENT TECHNOLOGIES
ARTIVION INC.
BECTON, DICKINSON AND CO.
BENITEC BIOPHARMA LTD.
CALADRIUS BIOSCIENCES
CELGENE CORP.
COMMENCE BIO
DEPUY SYNTHES (J&J)
DRÄGERWERK AG & CO. KGAA
EPIC SCIENCES INC.
GENEXINE
GERON
ILLUMINA INC.
IMMUNOCELLULAR THERAPEUTICS
INEX INNOVATIONS EXCHANGE PTE. LTD.
INIVATA LTD.
INTERPACE DIAGNOSTICS LLC
INVIVOSCRIBE INC.
MEDTRONIC PLC
MERCK KGAA
NOVARTIS AG
ONCOCYTE CORP.
ONCOMED PHARMACEUTICALS INC.
PLURISTEM THERAPEUTICS INC.
SILICON BIOSYSTEMS S.P.A
SPHERE FLUIDICS LTD.
THERMO FISHER SCIENTIFIC
VITATEX INC.

List of Tables

Summary Table : Global Market for Next-Generation Cancer Diagnostics, by Cancer Site, Through 2027
Table 1 : Large-Scale Initiatives: Cancer Diagnostics Industry
Table 2 : Liquid Biopsy Biomarker Classes
Table 3 : Key Trends in the Market for Next-Generation Cancer Diagnostics
Table 4 : Next-Generation Cancer Diagnostics Industry Subsectors
Table 5 : Diagnostic Market Segments
Table 6 : Next-Generation Diagnostics: Key Analysis Platforms
Table 7 : Analysis Platforms and Biomarker Types
Table 8 : DNA Microarray Technologies in Cancer Diagnostics
Table 9 : Design Features of Protein Microarray Technologies
Table 10 : Microfluidic LOAC Types Used in Cancer Diagnostics
Table 11 : Advanced Sequencing Technologies
Table 12 : Illumina Next Generation Sequencing Workflow
Table 13 : Thermo Fisher Scientific’s Next-Generation Sequencing Workflow
Table 14 : Main Ingredients of PCR Technology
Table 15 : PCR Process
Table 16 : Advantages of Droplet Digital PCR for Single-Cell Analysis
Table 17 : Liquid Biopsy: Forces Driving Growth, 2020
Table 18 : Limitations of Solid Biopsy in Cancer Applications
Table 19 : Low-Frequency Mutation Detection
Table 20 : Global Market for Next-Generation Cancer Diagnostics, by Cancer Site, Through 2027
Table 21 : Global Market for Next-Generation Cancer Diagnostics, by Purpose of Analysis, Through 2027
Table 22 : MRI and Liquid Biopsy Methods
Table 23 : Early Detection: Tissue of Origin Approaches
Table 24 : Global Market for Next-Generation Cancer Diagnostics, by Test Platform, Through 2027
Table 25 : FDA-Approved or CE-Marked Tests with Epigenetic Component
Table 26 : Global Market for PCR-Based Cancer Diagnostics, by Cancer Site, Through 2027
Table 27 : Global Market for NGS-Based Cancer Diagnostics, by Cancer Site, Through 2027
Table 28 : Global Market for Next-Generation Cancer Screening/Early Detection, by Cancer Site, Through 2027
Table 29 : Global Market for Next-Generation Cancer Diagnostics, by Cancer Site, Through 2027
Table 30 : Global Market for Next-Generation Cancer Monitoring, by Cancer Site, Through 2027
Table 31 : Global Market for Next-Generation Cancer Monitoring, by Cancer Site, Through 2027
Table 32 : Global Market for Breast Cancer Diagnostics, by Analysis Method, Through 2027
Table 33 : Global Market for Digestive Cancer Diagnostics, by Analysis Method, Through 2027
Table 34 : Global Market for Respiratory and Skin Cancer Diagnostics, by Analysis Method, Through 2027
Table 35 : Bladder Cancer Diagnostic Tests, 2020
Table 36 : Brain Cancer: Next-Generation Diagnostics Tests, 2020
Table 37 : Annual Breast Cancer Treatment Decisions, U.S., by Cancer Classification
Table 38 : Breast Cancer MDx Technology Platforms
Table 39 : Next-Generation Breast Cancer Tests, 2020
Table 40 : Next-Generation Human Papilloma Virus and Cervical Cancer Screening and Genotyping Tests
Table 41 : Ovarian Cancer Early Screening Formats, 2020
Table 42 : Ovarian Cancer: Next-Generation Diagnostics Tests, 2020
Table 43 : CRC Screening Tests
Table 44 : Colorectal Cancer: Next-Generation Diagnostic Tests
Table 45 : Cancer Unknown Primary: Next-Generation Diagnostic Tests, 2020
Table 46 : Gastric Cancer: Next-Generation Diagnostic Tests, 2020
Table 47 : Kidney Cancer: Next-Generation Diagnostic Tests, 2020
Table 48 : Leukemia and Myeloma: Next-Generation Diagnostic Tests, 2020
Table 49 : Liver Cancer: Next-Generation Diagnostic Tests, 2020
Table 50 : Five-Year Survival Rates for Non-Small Cell Lung Cancer
Table 51 : Lung Cancer: Next-Generation Diagnostic Tests, 2020
Table 52 : Lymphoma: Next-Generation Diagnostic Tests, 2020
Table 53 : Melanoma: Next-Generation Diagnostic Tests, 2021
Table 54 : Pan-Cancer: Next-Generation Diagnostic Tests, 2020
Table 55 : Prostate Cancer Next-Generation Diagnostic Tests
Table 56 : Thyroid Cancer: Next-Generation Diagnostics Tests, 2020
Table 57 : R&D: Next-Generation Cancer Diagnostics
Table 58 : Population Sequencing Projects
Table 59 : Global Market for Next-Generation Cancer Diagnostics, by Region, Through 2027
Table 60 : Select Patent Applications Filed on Next-Generation Cancer Diagnostics Technologies
Table 61 : Abbott Laboratories: Product Portfolio
Table 62 : Abbott Laboratories: Developments 2020-2022
Table 63 : AbbVie: Oncology Pharmaceutical Products Portfolio
Table 64 : AbbVie: Marketed Products
Table 65 : AbbVie: Key Developments, 2020-2021
Table 66 : Allergan plc: Marketed Products
Table 67 : Advanced Cell Diagnostics: Product Portfolio
Table 68 : Agilent Technologies: Developments, 2019-2022
Table 69 : Artivion Inc.: Product Portfolio
Table 70 : Artivion Inc.: Developments, 2020
Table 71 : Becton, Dickinson and Co.: Company Financials, 2021
Table 72 : Becton, Dickinson and Co.: Product Portfolio
Table 73 : Becton, Dickinson and Co.: Developments, 2017-2022
Table 74 : Benitec Biopharma: Product Portfolio
Table 75 : Caladrius Biosciences: Product Portfolio
Table 76 : Celgene Corp.: Product Portfolio
Table 77 : Commence Bio: Product Portfolio
Table 78 : DePuy Synthes: Product Portfolio
Table 79 : DePuy Synthes: Developments, 2019-2022
Table 80 : Dräger: Product Portfolio
Table 81 : Epic Sciences: Product Portfolio
Table 82 : Genexine: Product Portfolio
Table 83 : Geron: Product Portfolio
Table 84 : ImmunoCellular Therapeutics: Product Portfolio
Table 85 : Medtronic plc: Developments, 2019-2022
Table 86 : Novartis: Developments, 2019 and 2020
Table 87 : OncoCyte: Product Portfolio
Table 88 : OncoMed: Product Portfolio
Table 89 : Pluristem Therapeutics: Product Portfolio
Table 90 : Silicon Biosystems: Product Portfolio
Table 91 : Sphere Fluidics: Product Portfolio
Table 92 : Thermo Fisher Scientific: Product Portfolio
Table 93 : Thermo Fisher Scientific: Developments, 2019-2022
Table 94 : Vitatex: Product Portfolio

List of Figures

Summary Figure : Global Market for Next-Generation Cancer Diagnostics, by Cancer Site, 2019-2027
Figure 1 : Distribution of Cases by Stage at Diagnosis: Female Breast Cancer, 2021
Figure 2 : Global Incidence and Prevalence of Cancer Cases, by Cancer Site, 2022
Figure 3 : Snapshot of Next-Generation Cancer Diagnostics Technologies, by Region
Figure 4 : Global Market Shares of Next-Generation Cancer Diagnostics Technologies, by Region, 2027
Figure 5 : Becton, Dickinson and Co.: Revenue Share, by Business Segment, 2021
Figure 6 : Illumina Inc.: Annual Revenue, 2018-2021
Figure 7 : Illumina Inc.: Revenue Share, by Region/Country, 2021

Figure 8 : Illumina Inc.: Revenue Share, by Product Segment, 2021

△ 一番上に戻る